<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735707</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1189-1653</org_study_id>
    <secondary_id>2015-002340-14</secondary_id>
    <secondary_id>602525</secondary_id>
    <secondary_id>16/631</secondary_id>
    <secondary_id>APP1101719</secondary_id>
    <secondary_id>158584</secondary_id>
    <nct_id>NCT02735707</nct_id>
  </id_info>
  <brief_title>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</brief_title>
  <acronym>REMAP-CAP</acronym>
  <official_title>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MJM Bonten</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian and New Zealand Intensive Care Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Institute of New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Global Coalition for Adaptive Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for
      community-acquired pneumonia.

      The purpose of this study is to evaluate the effect of a range of interventions to improve
      outcome of patients admitted to intensive care with community-acquired pneumonia.

      In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple
      treatment modalities in the event of a respiratory pandemic resulting in critical illness.

      REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an
      intensive care unit (ICU) is associated with substantial mortality.

      Patients with pneumonia who are being treated in an ICU will receive therapy that consists of
      many different treatments, as many as 20 or 30. These treatments act together to treat both
      the infection and its effects on the body. When treating a patient, doctors choose from many
      different treatments, most of which are known or believed to be safe and effective. However,
      doctors don't always know which treatment option is the better one, as individuals or groups
      of individuals may respond differently. This study aims to help doctors understand which
      treatments work best.

      This clinical study has been designed in a way that allows the information from patients
      already in the study to help new patients joining the study. Most studies aren't able to do
      that. REMAP-CAP has been designed to:

        -  Evaluate multiple treatment strategies, at the same time, in the same patient.

        -  Reach platform conclusions when sufficient data is accrued, rather than when a
           pre-specified sample size is reached

        -  Utilise data that is already accrued to increase the likelihood that patients within the
           trial are randomised to treatments that are more likely to be beneficial

        -  New questions can be substituted into the trial as initial questions are answered,
           meaning that the trial can be perpetual or open-ended

        -  Interactions between interventions in different domains can be evaluated

      It is reasonable to presume that any pandemic respiratory infection of major significance to
      public health will manifest as life-threatening respiratory infection including Severe Acute
      Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission
      to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous
      pandemics and more localized outbreaks of respiratory emerging infections have resulted in
      severe CAP and ICU admission.

      Previous pandemics and outbreaks of emerging infectious diseases have outlined the urgent
      need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best
      treatment. However, there are substantial challenges associated with being able to organize
      such trials when the time of onset of a pandemic and its exact nature are unpredictable. As
      an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP
      is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing
      treatments as well as novel approaches.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Days alive and not receiving organ support in ICU</measure>
    <time_frame>Day 21</time_frame>
    <description>Primary end-point for patients with suspected or proven COVID-19 pandemic infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of life assessment</measure>
    <time_frame>6 months</time_frame>
    <description>EQ5D-5L and WHODAS 2.0 (not completed in all regions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of intubated patients who receive a tracheostomy</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destination at time of hospital discharge</measure>
    <time_frame>Free text Day 90</time_frame>
    <description>Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission to the index ICU during the index hospitalization</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organisation 8-point ordinal scale outcome</measure>
    <time_frame>Hospital discharge</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of multi-resistant organism colonisation/infection</measure>
    <time_frame>Day 90, censored at hospital discharge</time_frame>
    <description>Antibiotic Domain specific outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence clostridium difficile</measure>
    <time_frame>Day 90, censored at hospital discharge</time_frame>
    <description>Antibiotic Domain specific outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death</measure>
    <time_frame>Day 90, censored at hospital discharge</time_frame>
    <description>Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline influenza virus levels in upper and lower respiratory tract specimens</measure>
    <time_frame>Day 3, up to Day 7</time_frame>
    <description>Antiviral Domain specific outcome. Only required at selected sites.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing)</measure>
    <time_frame>Day 90, censored at hospital discharge</time_frame>
    <description>COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint</description>
  </other_outcome>
  <number_of_arms>33</number_of_arms>
  <enrollment type="Anticipated">7100</enrollment>
  <condition>Community-acquired Pneumonia, Influenza, COVID-19</condition>
  <arm_group>
    <arm_group_label>Corticosteroid Domain: fixed-duration Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive IV Hydrocortisone 50 mg every 6 hours for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid Domain:No systemic corticosteroid (no placebo)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient will receive no systemic corticosteroid for the treatment of CAP or its direct complications, up until study day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid Domain: shock dependant Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive hydrocortisone (50mg IV every 6 hours) while the patient is in septic shock.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Domain: Ceftriaxone + Macrolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftriaxone and site preferred macrolide will be administered for empiric antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Domain: Moxifloxacin or Levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin or levofloxacin will be administered for empiric antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Domain: Piperacillin-tazobactam + Macrolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin-tazobactam and site preferred macrolide will be administered for empiric antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Domain: Ceftaroline + Macrolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftaroline and site preferred macrolide will be administered for empiric antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Domain: Amoxicillin-clavulanate + Macrolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin-clavunate and site preferred macrolide will be administered for empiric antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macrolide Duration Domain: Standard course macrolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive macrolide therapy for 3-5 days. This arm is nested within the Antibiotic Domain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macrolide Duration Domain: Extended course macrolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antiviral agent active against influenza (no placebo)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient will receive no antiviral agent active against influenza, including oseltamivir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Five-day course of Oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive a five-day course of oseltamivir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-day course of oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive a ten-day course of oseltamivir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antiviral for COVID-19</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient will receive no antiviral agent intended to be active against SARS-CoV-2 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir for COVID-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive lopinavir/ritonavir (kaletra) 400/100mg enterally every 12 hours intended to be active against SARS-CoV-2 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine for COVID-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive hydroxychloroquine intended to be active against SARS-CoV-2 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + lopinavir/ritonavir for COVID-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive both hydroxychloroquine and lopinavir/ritonavir intended to be active against SARS-CoV-2 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No immune modulation for COVID-19</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive any immune modulating therapy intended to be active against COVID-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon-β1a for COVID-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Interferon-β1a intended to be active against COVID-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra (interleukin-1 receptor antagonist) for COVID-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive anakinra intended to be active against COVID-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed-duration higher dose Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive IV Hydrocortisone 100mg every 6 hours for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Tocilizumab intended to be active against COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Sarilumab intended to be active against COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Vitamin C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive vitamin c (no placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV Vitamin C (50mg/kg every 6 hours for 16 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care Thromboprophylaxis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive local standard care thromboprophylaxis for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapeutic anticoagulation with IV unfractionated heparin or subcutaneous low molecular weight heparin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No simvastatin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive simvastatin for up to 28 days while the patient remains in hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive simvastatin (80mg enterally once daily) for up to 28 days while the patient remains in hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No immunoglobulin against SARS-CoV-2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive any preparation of immunoglobulin intended to neutralise SARS-CoV-2 during the index hospitalisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive at least one, and not more than two, units of convalescent plasma within 48 hours of randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinician-preferred invasive ventilation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive invasive mechanical ventilation as determined by the treating clinician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocolised invasive mechanical ventilation strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive a protocolised invasive mechanical ventilation strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed-duration Hydrocortisone</intervention_name>
    <description>50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.</description>
    <arm_group_label>Corticosteroid Domain: fixed-duration Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shock-dependent hydrocortisone</intervention_name>
    <description>Patient will receive 50mg IV hydrocortisone every 6 hours while the patient is in septic shock</description>
    <arm_group_label>Corticosteroid Domain: shock dependant Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.</description>
    <arm_group_label>Antibiotic Domain: Ceftriaxone + Macrolide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin or Levofloxacin</intervention_name>
    <description>The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.</description>
    <arm_group_label>Antibiotic Domain: Moxifloxacin or Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-tazobactam</intervention_name>
    <description>The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.</description>
    <arm_group_label>Antibiotic Domain: Piperacillin-tazobactam + Macrolide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftaroline</intervention_name>
    <description>The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Ceftaroline is not available at commencement</description>
    <arm_group_label>Antibiotic Domain: Ceftaroline + Macrolide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulanate</intervention_name>
    <description>The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.</description>
    <arm_group_label>Antibiotic Domain: Amoxicillin-clavulanate + Macrolide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macrolide administered for 3-5 days</intervention_name>
    <description>Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.
The dosing of and route of administration is not protocolised, the following guidance is provided:
Initial IV administration of a macrolide is strongly preferred
The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.</description>
    <arm_group_label>Macrolide Duration Domain: Standard course macrolide</arm_group_label>
    <other_name>Standard course macrolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macrolide administered for up to 14 days</intervention_name>
    <description>Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).
The dosing of and route of administration is not protocolised, the following guidance is provided:
Initial IV administration of a macrolide is strongly preferred
The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.</description>
    <arm_group_label>Macrolide Duration Domain: Extended course macrolide</arm_group_label>
    <other_name>Extended course macrolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Five-days oseltamivir</intervention_name>
    <description>Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)</description>
    <arm_group_label>Five-day course of Oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ten-days oseltamivir</intervention_name>
    <description>Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)</description>
    <arm_group_label>10-day course of oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.</description>
    <arm_group_label>Lopinavir/ritonavir for COVID-19</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).</description>
    <arm_group_label>Hydroxychloroquine for COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine + lopinavir/ritonavir</intervention_name>
    <description>Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).</description>
    <arm_group_label>Hydroxychloroquine + lopinavir/ritonavir for COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-β1a</intervention_name>
    <description>IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.</description>
    <arm_group_label>Interferon-β1a for COVID-19</arm_group_label>
    <other_name>IFN-β1a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered very 6 hours.
In patients with renal impairment, anakinra will be administered on alternate days.</description>
    <arm_group_label>Anakinra (interleukin-1 receptor antagonist) for COVID-19</arm_group_label>
    <other_name>Interleukin-1 receptor antagonist (IL-1Ra)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed-duration higher dose Hydrocortisone</intervention_name>
    <description>100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.</description>
    <arm_group_label>Fixed-duration higher dose Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.</description>
    <arm_group_label>Sarilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Vitamin C 50mg/kg administered IV every 6 hours for 16 doses</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic anticoagulation</intervention_name>
    <description>Patients will be administered either low molecular weight heparin or unfractionated heparin to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.</description>
    <arm_group_label>Therapeutic Anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Patients will recieve at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.</description>
    <arm_group_label>Convalescent plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Protocolised mechanical ventilation strategy</intervention_name>
    <description>See Domain Specific Appendix for a complete description of protoclised invasive mechanical ventilation strategy.</description>
    <arm_group_label>Protocolised invasive mechanical ventilation strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        REMAP-CAP PLATFORM INCLUSION CRITERIA:

          1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission
             with:

               1. symptoms or signs or both that are consistent with lower respiratory tract
                  infection AND

               2. Radiological evidence of new onset consolidation (in patients with pre-existing
                  radiological changes, evidence of new infiltrate)

          2. Up to 48 hours after ICU admission, receiving organ support with one or more of:

               1. Non-invasive or Invasive ventilatory support;

               2. Receiving infusion of vasopressor or inotropes or both

        PLATFORM EXCLUSION CRITERIA:

          1. Healthcare-associated pneumonia:

               1. Prior to this illness, is known to have been an inpatient in any healthcare
                  facility within the last 30 days

               2. Resident of a nursing home or long term care facility

          2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more
             of the patient, substitute decision maker or attending physician are not committed to
             full active treatment

          3. Previous participation in this REMAP within the last 90 days

        REMAP-COVID PLATFORM INCLUSION CRITERIA

        1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or
        proven pandemic infection.

        REMAP-COVID PLATFORM EXCLUSION CRITERIA

          1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more
             of the patient, substitute decision maker or attending physician are not committed to
             full active treatment

          2. Patient is expected to be discharged from hospital today or tomorrow

          3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute
             illness due to suspected or proven pandemic infection.

          4. Previous participation in this REMAP within the last 90 days

        DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

        Each domain may have additional eligibility criteria. Refer to the study website for more
        information (www.remapcap.org).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Webb, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Monash University, Study Chair REMAP-CAP Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colin McArthur, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Bonten, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht, Study Chair REMAP-CAP Europe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lennie Derde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht, Coordinating Investigator REMAP-CAP Europe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marshall Marshall, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angus Derek, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cameron Green</last_name>
    <email>info@remapcap.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wilma Van Bentum-Puijk, MSc</last_name>
    <phone>+31 (0) 88 755 5555</phone>
    <email>prepare_icu@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Centre</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mongomery</last_name>
      <email>stephaniemontgomery@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>8808</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Darwin Hospital,</name>
      <address>
        <city>Darwin</city>
        <state>Northern Territory</state>
        <zip>0810</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Logan Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4131</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toowoomba Hospital</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bendigo Hospital</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hosptial Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital Midland</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6056</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital Murdoch</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Bourgeois, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Charleroi - Hôpital Civil Marie Curie</name>
      <address>
        <city>Charleroi</city>
        <zip>6042</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Biston, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Jorens, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Depuydt, Prof.</last_name>
      <email>Pieter.Depuydt@UGent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Cook, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Lamontagne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital Unity Health Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Marshall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General County Hospital Požega</name>
      <address>
        <city>Požega</city>
        <zip>34000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdravko Andrić, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Vujaklija Brajković, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital for Infectious Diseases</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Barsić, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Witzenrath, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin - Nephrologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André Finn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenz Reill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Pester</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gernot Rohde, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Klug, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sascha David, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias W. Pletz, Prof. Dr.</last_name>
      <email>mathias.pletz@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirak Petros, Prof. Dr.</last_name>
      <email>Sirak.Petros@uniklinik-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts Klinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siri Göpel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Weismann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jósa András County Hospital</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gábor Szigligeti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc Kórház - Veszprem County Hospital</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Béla Gál, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Almási Balogh Pál Kórház</name>
      <address>
        <city>Ózd</city>
        <zip>3600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>János Bélteczki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ger Curley, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alistair Nichol, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>alistair.nichol@ucd.ie</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Laffey, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura van Gulik, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Simons, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evert De Jonge, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>e.de_jonge@lumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Hoiting, M.D.</last_name>
    </contact>
    <contact_backup>
      <email>O.Hoiting@cwz.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeroen Schouten, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bonten, Prof.</last_name>
      <phone>+31 88 75 573 94</phone>
      <email>M.J.M.Bonten@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lennie Derde, MD</last_name>
      <phone>+31 (0)88 755 5555</phone>
      <email>L.P.G.Derde@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Everitt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CVICU, Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shay McGuinness, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DCCM, Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin McArthur, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2104</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Williams, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seton Henderson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Martynoga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotorua Hospital</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Buehner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Browne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington Regional Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Young, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whangarei Hospital</name>
      <address>
        <city>Whangarei</city>
        <zip>0148</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Perry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Medio Tejo</name>
      <address>
        <city>Abrantes</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuno Catorze, M.D.</last_name>
    </contact>
    <contact_backup>
      <email>nunocatorze@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Lusíadas Lisbon</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nunes Nunes, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital of Infectious and Tropical Diseases &quot;Dr. Victor Babes&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simin-Aysel Florescu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Hospital del Mar d'Investigacions Mèdiques</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosana Munoz, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Leon-Lopez, M.D.</last_name>
    </contact>
    <contact_backup>
      <email>rafael.leon.lop@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antony Ashton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matt Thomas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Bassford, MD</last_name>
      <email>christopher.bassford@uhcw.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Darlington Memorial Hospital</name>
      <address>
        <city>Darlington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Limb, MD</last_name>
      <email>j.limb@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Limb, MD</last_name>
      <email>j.limb@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elankumaran Paramasivam, MD</last_name>
      <email>eparamasivam@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Golden, MD</last_name>
      <email>david.golden@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Henning, MD</last_name>
      <email>jeremy.henning@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milton Keynes University Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Stewart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Wilkinson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre - Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Harvey, MD</last_name>
      <email>Daniel.harvey@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poole Hospital NHS Foundation Trust</name>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Reschreiter, MD</last_name>
      <email>henrik.reschreiter@poole.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pogson, MD</last_name>
      <email>david.pogson@porthosp.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Walden, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farooq Brohi, MD</last_name>
      <email>farooq.brohi@nth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Spivey, MD</last_name>
      <email>michaelspivey@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust</name>
      <address>
        <city>Tunbridge Wells</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Golden, MD</last_name>
      <email>david.golden@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Carter, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.prepare-europe.eu/About-us/Workpackages/Workpackage-5</url>
    <description>PREPARE website</description>
  </link>
  <link>
    <url>http://www.remapcap.org</url>
    <description>REMAP-CAP Study Website</description>
  </link>
  <link>
    <url>https://www.captic.ca/the-remap-cap-trial</url>
    <description>CAPTIC Website</description>
  </link>
  <link>
    <url>https://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.202003-192SD</url>
    <description>Protocol publication</description>
  </link>
  <link>
    <url>http://www.atsjournals.org/doi/10.1513/AnnalsATS.202003-192SD</url>
    <description>REMAP-CAP Protocol manuscript</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>MJM Bonten</investigator_full_name>
    <investigator_title>Prof. Medical Microbiology</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Levofloxacin</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Ceftriaxone</keyword>
  <keyword>Piperacillin-tazobactam</keyword>
  <keyword>Ceftaroline</keyword>
  <keyword>Amoxicillin-clavulanate</keyword>
  <keyword>Oseltamivir</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Influenza</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Critical care</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Therapeutic Anticoagulation</keyword>
  <keyword>Statin</keyword>
  <keyword>Invasive Mechanical Ventilation</keyword>
  <keyword>Convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Ceftaroline fosamil</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

